3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
45
Breast Neoplasms
15
Leiomyoma
3
Cardiovascular Diseases
3
Polycystic Ovary Syndrome
2
Neoplasms
2
Endometrial Neoplasms
2
Advanced Breast Cancer
2
Stage II Prostate Adenocarcinoma
1
Sexual Dysfunctions, Psychological
1
Sarcopenia
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Oligometastatic Prostate Carcinoma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Metabolic Syndrome
1
Metabolic Diseases
1
Kallmann Syndrome
1
Inflammatory Breast Neoplasms
1
Infertility
1
Hypogonadism
1
Hyperprolactinemia
1
Interventions
Cyclophosphamide
23
Paclitaxel
19
Epirubicin
14
Doxorubicin
13
Carboplatin
13
Trastuzumab
12
Docetaxel
10
Taxes
9
Albumin-Bound Paclitaxel
7
pembrolizumab
5
Radiotherapy
5
Fluorouracil
5
Filgrastim
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
pertuzumab
4
Neoadjuvant Therapy
4
Cisplatin
4
eribulin
3
Thiotepa
3
Tamoxifen
3
Panitumumab
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Flow Cytometry
3
Capecitabine
3
Biopsy
3
sargramostim
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Inflammatory Breast Neoplasms
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled